A new recombinant factor VIII: from genetics to clinical use

A new recombinant factor VIII: from genetics to clinical use

from genetics to clinical use".1 The article provided a timely review of recent advances and developments in the treatment of hemophilia A with recombinant factor VIII (rFVIII).1 However, when reviewing licensed rFVIII products, Santagostino1 did not include Human-cl rhFVIII (simoctocog alfa, N...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug design, development and therapy development and therapy, 2015-01, Vol.9, p.3817-3819
Hauptverfasser: Kannicht, Christoph, Kohla, Guido, Tiemeyer, Maya, Walter, Olaf, Sandberg, Helena
Format: Artikel
Sprache:eng
Schlagworte:
Animals
Coagulation factors
Factor VIII - genetics
Factor VIII - therapeutic use
Genetics
Hemophilia A - therapy
Humans
Letter
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3819
container_issue
container_start_page 3817
container_title Drug design, development and therapy
container_volume 9
creator Kannicht, Christoph
Kohla, Guido
Tiemeyer, Maya
Walter, Olaf
Sandberg, Helena
description from genetics to clinical use".1 The article provided a timely review of recent advances and developments in the treatment of hemophilia A with recombinant factor VIII (rFVIII).1 However, when reviewing licensed rFVIII products, Santagostino1 did not include Human-cl rhFVIII (simoctocog alfa, Nuwiq®).2-4 Nuwiq® is a new-generation rFVIII protein produced in HEK 293 F cells that was approved by the European Medicines Agency in July 2014 for the prevention and treatment of bleeds in hemophilia A patients of all ages.5 Read the original article
doi_str_mv 10.2147/DDDT.S85608
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4517516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A448157792</galeid><sourcerecordid>A448157792</sourcerecordid><originalsourceid>FETCH-LOGICAL-c590t-82b1380ca5a075a4e224a135ca651df5543908ba8054e276dc35d373b1007b123</originalsourceid><addsrcrecordid>eNptktuLEzEUxoMo7kWffJeAIAvSmuskIyKUrZfCgg-uvoZM5kybZSapycyK_70pXXdbkTwknPP7viQfB6EXlMwZFertcrm8nn_TsiL6ETqlVKmZ1po-PjifoLOcbwipeMXIU3TCKsZqIfgper_AAX7hBC4OjQ82jLizbowJ_1itVu9wl-KA1xBg9C7jMWLX--Cd7fGU4Rl60tk-w_O7_Rx9__Tx-vLL7Orr59Xl4mrmZE3GmWYN5Zo4Ky1R0gpgTFjKpbOVpG0npeA10Y3VRJaeqlrHZcsVbyghqqGMn6MPe9_t1AzQOghjsr3ZJj_Y9NtE681xJ_iNWcdbIyRVklbFgOwN2ngL2wQ5H4kfqiUFw1jRFMnF3Z0p_pwgj2bw2UHf2wBxyoYqQnVNayoK-uof9CZOKZREiherpNC1lA_U2vZgfOhiearbmZqFEJpKperdV-f_ocpqYfAuBuh8qR8JXh8INmD7cZNjP40-hnwMvtmDLsWcE3T3EVBidoNkdoNk9oNU6JeHkd-zfyeH_wH5Er-3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2226548955</pqid></control><display><type>article</type><title>A new recombinant factor VIII: from genetics to clinical use</title><source>MEDLINE</source><source>DOVE Medical Press Journals</source><source>DOAJ Directory of Open Access Journals</source><source>Taylor &amp; Francis Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Kannicht, Christoph ; Kohla, Guido ; Tiemeyer, Maya ; Walter, Olaf ; Sandberg, Helena</creator><creatorcontrib>Kannicht, Christoph ; Kohla, Guido ; Tiemeyer, Maya ; Walter, Olaf ; Sandberg, Helena</creatorcontrib><description>from genetics to clinical use".1 The article provided a timely review of recent advances and developments in the treatment of hemophilia A with recombinant factor VIII (rFVIII).1 However, when reviewing licensed rFVIII products, Santagostino1 did not include Human-cl rhFVIII (simoctocog alfa, Nuwiq®).2-4 Nuwiq® is a new-generation rFVIII protein produced in HEK 293 F cells that was approved by the European Medicines Agency in July 2014 for the prevention and treatment of bleeds in hemophilia A patients of all ages.5 Read the original article</description><identifier>ISSN: 1177-8881</identifier><identifier>EISSN: 1177-8881</identifier><identifier>DOI: 10.2147/DDDT.S85608</identifier><identifier>PMID: 26229443</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Animals ; Coagulation factors ; Factor VIII - genetics ; Factor VIII - therapeutic use ; Genetics ; Hemophilia A - therapy ; Humans ; Letter</subject><ispartof>Drug design, development and therapy, 2015-01, Vol.9, p.3817-3819</ispartof><rights>COPYRIGHT 2015 Dove Medical Press Limited</rights><rights>2015. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Kannicht et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c590t-82b1380ca5a075a4e224a135ca651df5543908ba8054e276dc35d373b1007b123</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517516/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517516/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,3849,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26229443$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kannicht, Christoph</creatorcontrib><creatorcontrib>Kohla, Guido</creatorcontrib><creatorcontrib>Tiemeyer, Maya</creatorcontrib><creatorcontrib>Walter, Olaf</creatorcontrib><creatorcontrib>Sandberg, Helena</creatorcontrib><title>A new recombinant factor VIII: from genetics to clinical use</title><title>Drug design, development and therapy</title><addtitle>Drug Des Devel Ther</addtitle><description>from genetics to clinical use".1 The article provided a timely review of recent advances and developments in the treatment of hemophilia A with recombinant factor VIII (rFVIII).1 However, when reviewing licensed rFVIII products, Santagostino1 did not include Human-cl rhFVIII (simoctocog alfa, Nuwiq®).2-4 Nuwiq® is a new-generation rFVIII protein produced in HEK 293 F cells that was approved by the European Medicines Agency in July 2014 for the prevention and treatment of bleeds in hemophilia A patients of all ages.5 Read the original article</description><subject>Animals</subject><subject>Coagulation factors</subject><subject>Factor VIII - genetics</subject><subject>Factor VIII - therapeutic use</subject><subject>Genetics</subject><subject>Hemophilia A - therapy</subject><subject>Humans</subject><subject>Letter</subject><issn>1177-8881</issn><issn>1177-8881</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptktuLEzEUxoMo7kWffJeAIAvSmuskIyKUrZfCgg-uvoZM5kybZSapycyK_70pXXdbkTwknPP7viQfB6EXlMwZFertcrm8nn_TsiL6ETqlVKmZ1po-PjifoLOcbwipeMXIU3TCKsZqIfgper_AAX7hBC4OjQ82jLizbowJ_1itVu9wl-KA1xBg9C7jMWLX--Cd7fGU4Rl60tk-w_O7_Rx9__Tx-vLL7Orr59Xl4mrmZE3GmWYN5Zo4Ky1R0gpgTFjKpbOVpG0npeA10Y3VRJaeqlrHZcsVbyghqqGMn6MPe9_t1AzQOghjsr3ZJj_Y9NtE681xJ_iNWcdbIyRVklbFgOwN2ngL2wQ5H4kfqiUFw1jRFMnF3Z0p_pwgj2bw2UHf2wBxyoYqQnVNayoK-uof9CZOKZREiherpNC1lA_U2vZgfOhiearbmZqFEJpKperdV-f_ocpqYfAuBuh8qR8JXh8INmD7cZNjP40-hnwMvtmDLsWcE3T3EVBidoNkdoNk9oNU6JeHkd-zfyeH_wH5Er-3</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Kannicht, Christoph</creator><creator>Kohla, Guido</creator><creator>Tiemeyer, Maya</creator><creator>Walter, Olaf</creator><creator>Sandberg, Helena</creator><general>Dove Medical Press Limited</general><general>Taylor &amp; Francis Ltd</general><general>Dove Press</general><general>Dove Medical Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7XB</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>KB0</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>A new recombinant factor VIII: from genetics to clinical use</title><author>Kannicht, Christoph ; Kohla, Guido ; Tiemeyer, Maya ; Walter, Olaf ; Sandberg, Helena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c590t-82b1380ca5a075a4e224a135ca651df5543908ba8054e276dc35d373b1007b123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Coagulation factors</topic><topic>Factor VIII - genetics</topic><topic>Factor VIII - therapeutic use</topic><topic>Genetics</topic><topic>Hemophilia A - therapy</topic><topic>Humans</topic><topic>Letter</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kannicht, Christoph</creatorcontrib><creatorcontrib>Kohla, Guido</creatorcontrib><creatorcontrib>Tiemeyer, Maya</creatorcontrib><creatorcontrib>Walter, Olaf</creatorcontrib><creatorcontrib>Sandberg, Helena</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drug design, development and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kannicht, Christoph</au><au>Kohla, Guido</au><au>Tiemeyer, Maya</au><au>Walter, Olaf</au><au>Sandberg, Helena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A new recombinant factor VIII: from genetics to clinical use</atitle><jtitle>Drug design, development and therapy</jtitle><addtitle>Drug Des Devel Ther</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>9</volume><spage>3817</spage><epage>3819</epage><pages>3817-3819</pages><issn>1177-8881</issn><eissn>1177-8881</eissn><abstract>from genetics to clinical use".1 The article provided a timely review of recent advances and developments in the treatment of hemophilia A with recombinant factor VIII (rFVIII).1 However, when reviewing licensed rFVIII products, Santagostino1 did not include Human-cl rhFVIII (simoctocog alfa, Nuwiq®).2-4 Nuwiq® is a new-generation rFVIII protein produced in HEK 293 F cells that was approved by the European Medicines Agency in July 2014 for the prevention and treatment of bleeds in hemophilia A patients of all ages.5 Read the original article</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>26229443</pmid><doi>10.2147/DDDT.S85608</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1177-8881
ispartof Drug design, development and therapy, 2015-01, Vol.9, p.3817-3819
issn 1177-8881
1177-8881
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4517516
source MEDLINE; DOVE Medical Press Journals; DOAJ Directory of Open Access Journals; Taylor & Francis Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access
subjects Animals
Coagulation factors
Factor VIII - genetics
Factor VIII - therapeutic use
Genetics
Hemophilia A - therapy
Humans
Letter
title A new recombinant factor VIII: from genetics to clinical use
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T17%3A53%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20new%20recombinant%20factor%20VIII:%20from%20genetics%20to%20clinical%20use&rft.jtitle=Drug%20design,%20development%20and%20therapy&rft.au=Kannicht,%20Christoph&rft.date=2015-01-01&rft.volume=9&rft.spage=3817&rft.epage=3819&rft.pages=3817-3819&rft.issn=1177-8881&rft.eissn=1177-8881&rft_id=info:doi/10.2147/DDDT.S85608&rft_dat=%3Cgale_pubme%3EA448157792%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2226548955&rft_id=info:pmid/26229443&rft_galeid=A448157792&rfr_iscdi=true